Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 4 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 4

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 14NET 5Gastrointestinal 3Genitourinary 2Lymphoid 1Dermatologic 1

Conditions

Neuroendocrine Tumors 3Gastro-enteropancreatic neuroendocrine tumor 2Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Neoplasms 1Melanoma 1Lymphoma, Follicular 1Dumping Syndrome 1Acromegaly 1

Interventions

Everolimus 18lutetium Lu 177 dotatate 9lanreotide 8surufatinib 7Octreotide 7pasireotide 5amino-acid, glucose, and electrolyte solution 5Sunitinib 5Temozolomide 4Data Collection 4pembrolizumab 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2fosbretabulin 2arginyllysine 2anlotinib 2Paclitaxel 2PM 01183 2Lutetium-177 2Lutetium 2Irinotecan 2Injections 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × pasireotide × NET × Clear all
NCT06784752 2026-04-30

NETTER-3

Novartis

Phase 3 Recruiting
240 enrolled
EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01364415 2020-12-21

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Novartis

Phase 1 Completed
29 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01590199 2019-04-16

MACS2002

Novartis

Phase 1 Completed
18 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡